184 completed. 184 Phase 2, 21 Phase 1, 9 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 184 | Completed 184 |
| Phase 1 | 21 | Completed 21 |
| Phase 3 | 9 | Completed 9 |
Follow Rhinitis, Allergic: new trials by email Literature Review of Rhinitis, Allergic trials Research Report on Rhinitis, Allergic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis INI-2004, Placebo - Allergic Rhinitis Due to Allergens, Rhinitis Allergic | Phase 2 | Completed | Inimmune Corporation | 78 | 2026-01-19 | 2026-04-29 |
| A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis SHR-1819 Injection, SHR-1819 Injection Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 108 | 2025-08-06 | 2026-08-27 |
| Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis TQC2938 injection, TQC2938 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 136 | 2025-07-31 | 2026-02-10 |
| M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis M-Gard, Placebo - Allergic Rhinitis Due to Grass Pollens | Phase 2 | Completed | RDC Clinical Pty Ltd | 20 | 2025-06-27 | 2026-03-06 |
| A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Placebo (twice daily) - Seasonal Allergic Rhinitis | Phase 2 | Completed | Prime Gene Therapeutics Co., Ltd. | 179 | 2025-03-12 | 2026-09-09 |
| Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis TQH2722 injection, TQH2722 Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 169 | 2025-03-10 | 2025-08-12 |
| Phase II Study of JT002 in the Treatment of Seasonal Allergic Rhinitis in Adults JT002 Nasal spray, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Shanghai JunTop Biosciences Co., LTD | 370 | 2025-02-24 | 2025-06-11 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal | Phase 1 / Phase 2 | Completed | AO GENERIUM | 150 | 2024-10-07 | 2026-09-21 |
| Azelastine Allergen Chamber - Onset of Action Study Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray, Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray - Seasonal Allergic Rhinitis | Phase 2 | Completed | MEDA Pharma GmbH & Co. KG | 84 | 2023-10-30 | 2024-03-20 |
| Study of CM310 in Patients With Allergic Rhinitis CM310 - Allergic Rhinitis | Phase 2 | Completed | Keymed Biosciences Co.Ltd | 100 | 2023-08-23 | 2024-11-08 |
| Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult LP-003 dose 1, LP-003 dose 2, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Longbio Pharma | 180 | 2023-07-06 | 2025-12-15 |
| A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis Interleukin-4 receptor responders 1, Interleukin-4 receptor responders 2, Placebo - Allergic Rhinitis | Phase 2 | Completed | Beijing Tongren Hospital | 93 | 2022-08-17 | 2023-10-19 |
| Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants REGN5713, REGN5714, REGN5715 - Allergic Rhinitis, Conjunctivitis | Phase 2 | Completed | Regeneron Pharmaceuticals | 217 | 2022-08-15 | 2024-11-19 |
| Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis PA9159 nasal spray solution, 10 μg once daily for 14 days, PA9159 nasal spray solution, 20 μg once daily for 14 days, PA9159 nasal spray solution, 40 μg once daily for 14 days - Allergic Rhinitis | Phase 2 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 204 | 2022-04-15 | 2023-02-01 |
| The Effects of Using Yupingfeng Powder with Variation for the Treatment of Allergic Rhinitis Yupingfeng Powder granules, Placebo - Allergic Rhinitis | Phase 2 | Completed | Prof. Lin Zhixiu | 58 | 2022-04-12 | 2024-11-07 |
| AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis AllerPops - Allergic Rhinitis | Phase 2 | Completed | AllerPops Corp | 72 | 2022-04-05 | 2023-07-24 |
| Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Polvac Grass+Rye, Saline 0.9% - Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma | Phase 1 / Phase 2 | Completed | University of Zurich | 60 | 2022-02-10 | 2025-05-21 |
| Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis IRL201104, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Revolo Biotherapeutics | 63 | 2021-11-04 | 2026-09-21 |
| To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray 140/100 μg Azelastine hydrochloride/Beclomethasone Dipropionate) - Seasonal Allergic Rhinitis | Phase 1 / Phase 2 | Completed | Humanis Saglık Anonim Sirketi | 48 | 2021-03-25 | 2023-12-13 |
| Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients Tregalizumab, Placebo - Allergy to House Dust Mite, Allergic Asthma | Phase 2 | Completed | T-Balance Therapeutics GmbH | 42 | 2020-12-09 | 2022-02-08 |
Showing 20 of 184. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (91) · Hypersensitivity (25) · Asthma (17) · Rhinitis (16) · Rhinitis, Allergic, Perennial (14) · Dust Mite Allergy (10) · Conjunctivitis, Allergic (7) · Sneezing (6) · Rhinorrhea (4) · Conjunctivitis (3) · Nasal Obstruction (3) · Eczema (2) · Immune System Diseases (2) · Inflammation (2)
Hypersensitivity, Immediate (184) · Nose Diseases (184) · Otorhinolaryngologic Diseases (184) · Respiratory Hypersensitivity (183) · Respiratory Tract Diseases (183) · Immune System Diseases (182) · Rhinitis (168) · Hypersensitivity (159) · Bronchial Diseases (17) · Infections (17) · Lung Diseases (17) · Lung Diseases, Obstructive (17) · Respiratory Tract Infections (17) · Rhinitis, Allergic, Perennial (10)
Cetirizine (7) · 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide (5) · Fluticasone (5) · Loratadine (5) · azelastine (5) · Budesonide (4) · Mometasone Furoate (4) · Sublingual Immunotherapy (4) · bilastine (4) · Antigens, Dermatophagoides (3) · Nasal Sprays (3) · Serum Albumin, Human (3) · fexofenadine (3) · montelukast (3) · (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (2)
GlaxoSmithKline (14) · HAL Allergy (6) · Laboratorios Leti, S.L. (5) · Merck Sharp & Dohme LLC (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · ALK-Abelló A/S (4) · AstraZeneca (4) · Bausch & Lomb Incorporated (4) · BioTech Tools S.A. (4) · Capnia, Inc. (4) · Circassia Limited (4) · Faes Farma, S.A. (4) · Novartis Pharmaceuticals (4) · Organon and Co (4) · Stallergenes Greer (4)
United States (35) · Canada (29) · Germany (27) · Austria (14) · Sweden (12) · United Kingdom (11) · China (10) · Spain (8) · Poland (6) · Belgium (5) · Denmark (5) · France (5) · Thailand (5) · Finland (3) · Hong Kong (3)
Lennart Greiff, MD, PhD (3) · Tim McNamara, PharmD (3) · Anish Bhatnagar, MD (2) · Bertil Andersson (2) · Deepen Patel, MD (2) · Dr Lynette Shek, Consultant (2) · Lars Olaf Cardell, Professor (2) · Miguel Blanca, MD, PhD (2) · Paul Ratner, MD (2)
PMID 19001265, PMID 24184147, PMID 34379802, PMID 39035788, PMID 14619332, PMID 16387596, PMID 17021320, PMID 17631952, PMID 17950857, PMID 18566548, PMID 18946234, PMID 19680119, PMID 19748656, PMID 19943178, PMID 20412135, PMID 20920778, PMID 22464647, PMID 22994348, PMID 23025511, PMID 23374268, PMID 23562197, PMID 23622121, PMID 23815103, PMID 24035151, PMID 24332218, PMID 24388010, PMID 24836393, PMID 24852424, PMID 24934402, PMID 24986270, PMID 25024716, PMID 25788949, PMID 25900517, PMID 26044169, PMID 26133030, PMID 26143019, PMID 26249767, PMID 26272281, PMID 26342289, PMID 26417901, PMID 26507708, PMID 26682038, PMID 27008542, PMID 27231527, PMID 27253988, PMID 27363578, PMID 27613466, PMID 27979028, PMID 28196255, PMID 28392807
2009 (3), 2008 (2), 2015 (2), 2005 (1), 2016 (1), 2019 (1), U01AI123337 (1)